Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Major Shareholder Sells $1,248,192.66 in Stock

Defense World ·  {{timeTz}}

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction on Friday, July 1st. The shares were sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now directly owns 3,888,452 shares of the company's stock, valued at $11,120,972.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Tpg Gp A, Llc also recently made the following trade(s):

Get Trevi Therapeutics alerts:
  • On Tuesday, July 5th, Tpg Gp A, Llc sold 63,569 shares of Trevi Therapeutics stock. The shares were sold at an average price of $3.11, for a total value of $197,699.59.
  • On Wednesday, June 29th, Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.74, for a total value of $126,390.72.
  • On Monday, May 2nd, Tpg Gp A, Llc sold 600 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.70, for a total value of $1,620.00.
  • On Thursday, April 28th, Tpg Gp A, Llc sold 7,271 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.77, for a total value of $20,140.67.

Shares of NASDAQ:TRVI opened at $3.79 on Friday. The stock has a market capitalization of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18. Trevi Therapeutics, Inc. has a 1-year low of $0.46 and a 1-year high of $3.86. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $2.40 and a two-hundred day moving average price of $1.74.

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.07. During the same period last year, the business earned ($0.43) EPS. As a group, equities analysts predict that Trevi Therapeutics, Inc. will post -0.81 EPS for the current year.

A number of research analysts recently issued reports on TRVI shares. Oppenheimer lifted their price target on Trevi Therapeutics to $12.00 in a report on Monday. Needham & Company LLC lifted their price target on Trevi Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, June 29th. Finally, Aegis assumed coverage on Trevi Therapeutics in a report on Tuesday, March 29th. They issued a "buy" rating and a $10.00 price target for the company.

Several institutional investors have recently bought and sold shares of TRVI. Commonwealth Equity Services LLC acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $33,000. WealthTrust Axiom LLC grew its position in shares of Trevi Therapeutics by 245.6% during the 1st quarter. WealthTrust Axiom LLC now owns 98,500 shares of the company's stock worth $216,000 after buying an additional 70,000 shares during the period. MAI Capital Management acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $3,391,000. Vanguard Group Inc. grew its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock worth $336,000 after buying an additional 10,780 shares during the period. Finally, State Street Corp acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $81,000. Institutional investors own 75.34% of the company's stock.

About Trevi Therapeutics (Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Read More

  • Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
  • 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
  • Credo Technology Stock is Rebounding
  • Investing In Preferred Stock vs. Common Stock
  • Profiting From 52 Week Low Stocks
  • Three Cheap Stocks The Insiders Are Buying

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top